Amgen Wins First EU Avastin Biosimilar Approval, But When Will It Launch?
Executive Summary
Partners Amgen and Allergan have become the first biosimilar developers to win EU approval for a copycat version of Roche's Avastin; commercialization preparation is underway but predicting a launch date for the product is more complicated.
You may also be interested in...
Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP. Their EU approval should now be a formality. Two new Shionogi treatments are set for approval, as are two orphan products – one from Medac, the other from AOP Orphan Pharmaceuticals. Pfizer got the OK for one biosimilar but has withdrawn an application for another.
Pharma Q2 Results Preview: AstraZeneca, Roche, Merck And BMS
Over two days, stakeholders will get a complete picture of the checkpoint inhibitor market as the four major immuno-oncology sponsors report second quarter sales and earnings.
Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings
There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).